Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant chemotherapy with or without celecoxib or trastuzumab in high-risk localized breast cancer
ISRCTN10059974Phase 2Completed
- Sponsor
- IFM Therapeutics
- Start
- Oct 2003
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin, cyclophosphamide, docetaxel, celecoxib and trastuzumab in breast cancer (3 arms), sponsored by IFM Therapeutics. Primary endpoint: Pathological response rate. Started Oct 2003; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN10059974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10059974.